Benzalkonium chloride
This article was originally published in The Tan Sheet
Executive Summary
FDA should not clear the ingredient for chronic use in health care antiseptic drug products due to a lack of data demonstrating long-term safety, Lonza's counsel says in an Aug. 3 letter. Responding to a citizen petition filed by International Laboratory Technology Corp. requesting GRAS/E status for the ingredient in OTC topical antimicrobial products, Lonza notes the agency has required data on chronic toxicity for a number of ingredients evaluated in the health care antiseptic drug products monograph, but the studies submitted by ILTC do not address long-term use. FDA currently considers benzalkonium chloride (.11%-.13%) a Category III ingredient - data insufficient to demonstrate safety/efficacy - except for short-term use (1"The Tan Sheet" April 24, p. 9)
You may also be interested in...
Benzalkonium Chloride Antimicrobial Handwash Kills 98% Of Staph - ILTC
Inclusion of benzalkonium chloride as a Category I ingredient in the tentative final monograph for OTC topical antimicrobial drug products is requested by International Laboratory Technology Corp. in a citizen petition submitted to FDA April 6.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands